Edition:
United Kingdom

VBI Vaccines Inc (VBIV.OQ)

VBIV.OQ on NASDAQ Stock Exchange Capital Market

1.89USD
18 Jan 2019
Change (% chg)

$-0.03 (-1.56%)
Prev Close
$1.92
Open
$1.95
Day's High
$1.96
Day's Low
$1.85
Volume
40,714
Avg. Vol
100,639
52-wk High
$4.34
52-wk Low
$1.20

Latest Key Developments (Source: Significant Developments)

VBI Vaccines Announces Phase 2 Clinical Study Design Of Its Prophylactic CMV Vaccine Candidate
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - VBI Vaccines Inc ::VBI VACCINES ANNOUNCES PHASE 2 CLINICAL STUDY DESIGN OF ITS PROPHYLACTIC CMV VACCINE CANDIDATE.VBI VACCINES INC - PHASE 2 STUDY IS EXPECTED TO BE A FORMAL DOSE-RANGING STUDY DESIGNED TO ASSESS SAFETY AND IMMUNOGENICITY OF THREE DIFFERENT DOSAGES.VBI VACCINES INC - FOLLOWING DISCUSSIONS WITH HEALTH CANADA, TOXICOLOGY STUDIES ARE UNDERWAY.VBI VACCINES - PLANS FOR PHASE 2 CLINICAL STUDY EVALUATING VBI-1501, CO'S PROPHYLACTIC CMV VACCINE CANDIDATE, POST POSITIVE DISCUSSIONS WITH HEALTH CANADA.  Full Article

VBI Vaccines Announces Pricing Of $37.5 Mln Public Offering
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - VBI Vaccines Inc ::VBI VACCINES ANNOUNCES PRICING OF $37.5 MILLION PUBLIC OFFERING.VBI VACCINES INC - PRICING 26.8 MILLION SHARES OFFERING AT US$1.40 PER SHARE.  Full Article

Vbi Vaccines Announces Proposed Public Offering Of Common Shares
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - VBI Vaccines Inc ::VBI VACCINES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.VBI VACCINES INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO PROGRESS RESEARCH AND DEVELOPMENT PROGRAMS.  Full Article

VBI Vaccines Appoints Christopher Mcnulty As CFO And Head Of Business Development
Wednesday, 15 Aug 2018 

Aug 15 (Reuters) - VBI Vaccines Inc ::VBI VACCINES APPOINTS CHRISTOPHER MCNULTY AS CHIEF FINANCIAL OFFICER AND HEAD OF BUSINESS DEVELOPMENT.SAYS CHRISTOPHER MCNULTY APPOINTED CFO.  Full Article

VBI Vaccines Q2 Loss Per Share $0.26
Thursday, 26 Jul 2018 

July 26 (Reuters) - VBI Vaccines Inc ::VBI VACCINES ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.26.Q2 REVENUE $200,000.Q2 REVENUE VIEW $679,000 -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.PIVOTAL PHASE 3 PROGRAM FOR SCI-B-VAC HEPATITIS B VACCINE CONTINUES TO ADVANCE TOWARDS TOPLINE DATA EXPECTED MID-YEAR 2019.VBI VACCINES - INITIAL DATA FROM PHASE 1/2A STUDY OF VBI-1901 FOR TREATMENT OF RECURRENT GLIOBLASTOMA EXPECTED H2 2018.ENDED Q2 WITH $41.1 MILLION IN CASH AND CASH EQUIVALENTS VERSUS $67.7 MILLION AS OF DEC 31, 2017.  Full Article

VBI Vaccines Files For Mixed Shelf Of Up To $150 Mln
Friday, 20 Jul 2018 

July 20 (Reuters) - VBI Vaccines Inc ::VBI VACCINES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING.  Full Article

VBI Vaccines Announces Completion Of Enrollment In Protect Phase 3 Clinical Study For Sci-B-Vac Hepatitis B Vaccine
Thursday, 19 Apr 2018 

April 19 (Reuters) - VBI Vaccines Inc ::VBI VACCINES ANNOUNCES COMPLETION OF ENROLLMENT IN PROTECT PHASE 3 CLINICAL STUDY FOR SCI-B-VAC® HEPATITIS B VACCINE.VBI VACCINES INC - TOPLINE DATA FROM PROTECT STUDY ARE EXPECTED MID-YEAR 2019.  Full Article

Vbi Vaccines Announces Voluntary Delisting From The Toronto Stock Exchange
Monday, 12 Mar 2018 

March 12 (Reuters) - Vbi Vaccines Inc ::VBI VACCINES ANNOUNCES VOLUNTARY DELISTING FROM THE TORONTO STOCK EXCHANGE.VBI VACCINES - BOARD DECIDED TO VOLUNTARILY DELIST FROM TSX DUE TO VERY LIMITED TRADING ACTIVITY OF CO'S SHARES ON TSX.VBI VACCINES - LIMITED TRADING ACTIVITY OF CO'S SHARES ON TSX NO LONGER JUSTIFIES COSTS REQUIRED TO MAINTAIN DUAL-LISTING.VBI VACCINES - CO WILL CONTINUE TO HAVE "SIGNIFICANT" OPERATIONAL PRESENCE IN OTTAWA, CANADA.VBI VACCINES INC - SHARES WILL BE DELISTED FROM TSX, EFFECTIVE AT CLOSE OF TRADING ON MARCH 23.  Full Article

VBI Vaccines Announces First Patient Dosing In Phase 3 Clinical Program For Sci-B-Vac Hepatitis B Vaccine
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Vbi Vaccines Inc ::VBI VACCINES ANNOUNCES FIRST PATIENT DOSING IN PHASE 3 CLINICAL PROGRAM FOR SCI-B-VAC HEPATITIS B VACCINE.VBI VACCINES SAYS HEADLINE DATA FROM THE 15-MONTH PHASE 3 PROGRAM EXPECTED IN Q2 2019.VBI VACCINES SAYS 4,800 SUBJECTS EXPECTED TO ENROLL IN TRIAL ACROSS TWO PHASE 3 STUDIES, PROTECT AND CONSTANT.VBI VACCINES SAYS EXPECT TO SUBMIT MARKETING AUTHORIZATION APPLICATIONS FOR SCI-B-VAC TO U.S., EUROPEAN, CANADIAN AUTHORITIES IN 2019.  Full Article

VBI Vaccines announces full exercise of option to purchase additional shares, upsized registered direct offering for proceeds of $71.9 mln
Monday, 30 Oct 2017 

Oct 30 (Reuters) - VBI Vaccines Inc -:VBI Vaccines announces full exercise of underwriters’ option to purchase additional shares and upsized registered direct offering for aggregate proceeds of $71.9 million.VBI Vaccines Inc - ‍in addition, VBI's previously announced concurrent registered direct offering was upsized from US$20.8 million to US$22.8 million​.  Full Article